Clinical study of Shenqi Fuzheng decoction directional penetration for the treatment of cancer pain in advanced lung cancer patients.

OBJECTIVE

The study aimed at analyzing the effect of Shenqi Fuzheng Decoction directional penetration for treating advanced lung cancer patients with cancer-related pain.

METHOD

Eighty-six cases with advanced lung cancer received in Zhoushan Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were divided randomly into a study group (n = 43) and control group (n = 43). Two groups were treated with the same conservative treatment plan, on the basis of which the control group treated with placebo, and study group received Shenqi Fuzheng Decoction directional penetration treatment. The cancer-related pain intensity, analgesic onset time, the frequency of pain outbreak, and analgesic duration were assessed and recorded. Before and after treatment, the cancer-related fatigue, quality of life, and Karnofsky Performance Status (KPS) score were assessed in two groups. Moreover, the adverse reactions of two groups during treatment were recorded.

RESULTS

Compared to the control group, the cancer-related pain intensity of the study group was reduced, the analgesic onset time was shortened, the frequency of pain outbreak was reduced, and the analgesic duration was prolonged (p < 0.05). After treatment, Piper Fatigue Scale (PFS) scores in the study group were lower than the control group, and the generic quality of life inventory-74 (GQOLI-74) and KPS scores in the study group were higher than the control group (p < 0.05). During the treatment period, no significant adverse reactions were observed in both groups (p > 0.05).

CONCLUSION

Shenqi Fuzheng Decoction directional penetration treatment has a remarkable effect in advanced lung cancer patients with cancer pain, which can relief the pain intensity, prolong the duration of pain relief, reduce the number of pain attacks, relieve patients' cancer-related fatigue, and improve patients' life quality and health status.

Copyright: © 2025 Permanyer.